AbbVie Inc. (ABBV)
| Market Cap | 290.83B |
| Revenue (ttm) | 54.32B |
| Net Income (ttm) | 4.86B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.72 |
| PE Ratio | 60.60 |
| Forward PE | 14.46 |
| Dividend | $6.20 (3.76%) |
| Ex-Dividend Date | Apr 12, 2024 |
| Volume | 107,479 |
| Open | 164.96 |
| Previous Close | 164.25 |
| Day's Range | 164.72 - 165.25 |
| 52-Week Range | 130.96 - 182.89 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 182.18 (+10.53%) |
| Earnings Date | Apr 26, 2024 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.86 billion, a decrease of -58.91%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $182.18, which is an increase of 10.53% from the latest price.
News
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multipl...
These four halal, Shariah-compliant stocks are best buys after Eid al-Fitr
If you want to invest in some new halal stocks, you know that finding companies compliant with Shariah law can be complicated.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“Abb...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible ...
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of ...
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company's possib...
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- All...
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing rev...
AbbVie to Host First-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.
Top three US healthcare stocks to buy in April
As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health. 1. Lilly (Eli) & Co.
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif. , April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebr...
Calls of the Day: Bank of America, Oracle, Abbvie and Pfizer
The Investment Committee debates the latest calls of the day and how to trade them.
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma...
NIMML Institute's TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie's Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
BLACKSBURG, Va.--(BUSINESS WIRE)--The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its ...
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
Allergan Aesthetics is raising the conversation on patient safety and ethical standards As part of its established Aesthetics-Ethics program, this year's Anti-Age Medicine World Congress (AMW C) launc...
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. ...
AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval
The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments conside...
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
- The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinu...
US FDA grants full approval to AbbVie's ovarian cancer therapy
The U.S. Food and Drug Administration (FDA) said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for adult patients with a type of ovarian and rela...
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , March 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024.
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatolog...
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING1 IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVi...
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET ® to enter into clinical trials. WALTHAM, Mass.
OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership
NANTES, France--(BUSINESS WIRE)--OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership.